Evidence map›Paper›PMID 40225909›Full record

ArticleNeuro-oncology advances

Assessing the dose of regadenoson required to transiently alter blood-brain barrier integrity in patients with infiltrating gliomas.

Stuart A Grossman, Carlos G Romo, Xiaobu Ye, Brian Kral, Roy E Strowd, Glenn Lesser, Catalina Raymond, Michaella Iacoboni, Serena Desideri, Joy Fisher and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Stuart A GrossmanDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-3726-7679
Carlos G RomoDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-0260-7047
Xiaobu YeDepartment of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Brian KralDepartment of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Roy E StrowdDepartment of Internal Medicine, Hematology and Oncology, Wake Forest University School of Medicine, Wake Forest, North Carolina, USA.
Glenn LesserDepartment of Internal Medicine, Hematology and Oncology, Wake Forest University School of Medicine, Wake Forest, North Carolina, USA.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers, Los Angeles, California, USA.ORCID https://orcid.org/0000-0003-2757-439X
Michaella IacoboniDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Serena DesideriDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Joy FisherDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Neeraja DandaDepartment of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory, Department of Radiological Sciences, Center for Computer Vision and Imaging Biomarkers, Los Angeles, California, USA.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Adult Brain Tumor Consortium (ABTC)UM1CA137443 · NCI · JOHNS HOPKINS UNIVERSITY · PI GROSSMAN, STUART A · 2014 to 2020
$9.7M
NCI NIH HHS P50 CA211015NCI NIH HHS UM1 CA137443
6 · The paper itself

Abstract

Background: The blood-brain barrier (BBB) severely limits the delivery of therapeutic agents to the brain. Regadenoson, a Food and Drug Administration-approved adenosine A2 agonist, transiently increases BBB permeability in rodents to a 70 kDa dextran. This multi-institutional, NIH-funded study examined regadenoson's ability to transiently alter BBB permeability in patients with gliomas. Methods: Adults with supratentorial gliomas at low risk for regadenoson complications were treated with 1 of the 7 dose levels known to be safe in humans. Successful BBB disruption was defined as a 10-fold increase in vascular permeability ( Results: Seven patients <45 years old with low-grade gliomas were accrued before the study was prematurely closed. Regadenoson was well tolerated. Following regadenoson, Conclusions: No dose of regadenoson significantly elevated Clinical Trial Registration: NCI Protocol #: Adult brain tumor consortium 1804, ClinicalTrials.gov Identifier:

Indexed as

adenosine agonistblood-brain barriergadoliniumgliomamagnetic resonance imaging (MRI)

Identifiers

PMID40225909
PMCPMC11992616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.